Publicacións en colaboración con investigadores/as de Fundación Jiménez Díaz (51)

2024

  1. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

2023

  1. Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

    Cancer Medicine, Vol. 12, Núm. 14, pp. 14892-14901

  2. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

    Blood Cancer Journal, Vol. 13, Núm. 1

  3. Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study)

    PharmacoEconomics, Vol. 41, Núm. 8, pp. 999-1010

  4. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

    Cancers, Vol. 15, Núm. 2

  5. Spontaneous Variation of Ventriculo-Atrial Interval after Tachycardia Induction: Determinants and Usefulness in the Diagnosis of Supraventricular Tachycardias with Long Ventriculoatrial Interval

    Journal of Clinical Medicine, Vol. 12, Núm. 2

2022

  1. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry

    Leukemia Research, Vol. 115

  2. Consensus on the Management of the COPD Patient in the COVID-19 Setting: COPD Forum Working Group

    Archivos de Bronconeumologia, Vol. 58, Núm. 11, pp. 776-779

  3. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  4. Corrigendum to “Prognosis of unexpected positive intraoperative cultures in arthroplasty revision: A large multicenter cohort” [Journal of Infection 83 (2021) 542–549] (Journal of Infection (2021) 83(5) (542–549), (S0163445321004527), (10.1016/j.jinf.2021.09.001))

    Journal of Infection

  5. EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1667-1684

  6. Effectiveness and Safety of Inhaled Antibiotics in Patients With Chronic Obstructive Pulmonary Disease. A Multicentre Observational Study

    Archivos de Bronconeumologia, Vol. 58, Núm. 1, pp. 11-21

  7. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

    Lung Cancer, Vol. 173, pp. 83-93

  8. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

    Blood Advances, Vol. 6, Núm. 4, pp. 1278-1295

2021

  1. Arguments in favour of excluding MDBGN from the European baseline series. In response to “Comment on MDBGN/DBDCB, the European baseline series, and EU legislation”

    Contact Dermatitis

  2. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

    Leukemia, Vol. 35, Núm. 6, pp. 1571-1585

  3. Impact of covid-19 on patients in radiotherapy oncology departaments in Spain

    Radiotherapy and Oncology

  4. Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD: Importance of Sex

    Chest, Vol. 160, Núm. 2, pp. 481-490

  5. Prognosis of unexpected positive intraoperative cultures in arthroplasty revision: A large multicenter cohort

    Journal of Infection, Vol. 83, Núm. 5, pp. 542-549

  6. Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study

    Contact dermatitis, Vol. 85, Núm. 5, pp. 572-577